Minomic is pleased to announce the publication of the company’s latest research paper supporting the utilisation of MiCheck® Prostate as an aid to diagnosing clinically significant prostate cancer.
It is clear there is strong clinical need to identify those patients with an elevated PSA who have clinically significant prostate cancer and would benefit from prostate biopsy.
MiCheck® Prostate identifies clinically significant prostate cancer with high sensitivity combined with a very high negative predictive value. MiCheck® Prostate could assist in reducing unnecessary prostate biopsies.
Read and download the article for free by clicking on this link before November 08, 2023 (no sign up, registration or fees are required): https://authors.elsevier.com/c/1hnd8_OWv~ZWBf
